Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease (Q46893339)

26 December 2017

title

Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease (English)

1 reference

26 December 2017

1 reference

9

Serge B Melançon

1 reference

26 December 2017

Josanne Cox-Brinkman

5

object named as

Josanne Cox-Brinkman

1 reference

26 December 2017

author name string

Christiane Auray-Blais

1

1 reference

26 December 2017

Denis Cyr

2

1 reference

26 December 2017

Aimé Ntwari

3

1 reference

26 December 2017

Michael L West

4

1 reference

26 December 2017

Daniel G Bichet

6

1 reference

26 December 2017

Dominique P Germain

7

1 reference

26 December 2017

Rachel Laframboise

8

1 reference

26 December 2017

Tracy Stockley

10

1 reference

26 December 2017

Joe T R Clarke

11

1 reference

26 December 2017

Régen Drouin

12

1 reference

26 December 2017

publication date

26 November 2007

1 reference

26 December 2017

Molecular Genetics and Metabolism

published in

1 reference

26 December 2017

volume

93

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

331-340

1 reference

26 December 2017

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Narrative review: Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Prevalence of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

High incidence of later-onset fabry disease revealed by newborn screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Novel trinucleotide deletion in Fabry's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Enzyme replacement in Fabry disease: the essence is in the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Cellular and tissue distribution of intravenously administered agalsidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

A biobank management model applicable to biomedical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Validation of a liquid chromatography tandem mass spectrometry assay for serum creatinine and comparison with enzymatic and Jaffe methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Simultaneous and rapid analysis of cyclosporin A and creatinine in finger prick blood samples using liquid chromatography tandem mass spectrometry and its application in C2 monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Quantitative determination of guanidinoacetate and creatine in dried blood spot by flow injection analysis-electrospray tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.10.001

10.1016/J.YMGME.2007.10.001

7 January 2021

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017